Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Syndax Pharmaceuticals (SNDX) Accumulated Depreciation & Amortization (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Accumulated Depreciation & Amortization for 12 consecutive years, with $429000.0 as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Depreciation & Amortization changed N/A year-over-year to $429000.0; the TTM value through Mar 2026 reached $429000.0, changed N/A, while the annual FY2025 figure was $425000.0, 1.43% up from the prior year.
  • Accumulated Depreciation & Amortization hit $429000.0 in Q1 2026 for Syndax Pharmaceuticals, up from $425000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $429000.0 in Q1 2026 and bottomed at $399000.0 in Q4 2022.
  • Average Accumulated Depreciation & Amortization over 5 years is $416600.0, with a median of $419000.0 recorded in 2024.
  • Year-over-year, Accumulated Depreciation & Amortization fell 9.93% in 2022 and then increased 3.01% in 2023.
  • Syndax Pharmaceuticals' Accumulated Depreciation & Amortization stood at $399000.0 in 2022, then rose by 3.01% to $411000.0 in 2023, then increased by 1.95% to $419000.0 in 2024, then increased by 1.43% to $425000.0 in 2025, then grew by 0.94% to $429000.0 in 2026.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $429000.0, $425000.0, and $419000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.